Tag: Antibody-Drug Conjugates (ADCs)

Market Analysis

Ambrx Biopharma’s Longtime Investors Reap 6,700% Gain on Johnson & Johnson’s Buyout Bid

Investors who have long believed in Ambrx Biopharma Inc. are now enjoying…

The Investment News Team

January 9, 2024